Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Plaque Type Psoriasis

In brief

This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis

Key facts

Study ID

NCT02074982

Run by

Novartis Pharmaceuticals

People needed

676

Starts

2014-02-26

Expected to finish

2016-06-29

Last updated by the study team

2017-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with moderate to severe plaque type psoriasis for at least 6 months before randomization
• patients eligible for systemic therapy with inadequately controlled psoriasis

You may not qualify if…

• forms of sporiasis other than plaque type psoriasis
• previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting (IL)-17A or IL-17RA
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Mobile, Alabama, United States
• Novartis Investigative Site — Phoenix, Arizona, United States
• Novartis Investigative Site — Hot Springs, Arkansas, United States
• Novartis Investigative Site — Los Angeles, California, United States
• Novartis Investigative Site — Oceanside, California, United States
• Novartis Investigative Site — Santa Monica, California, United States
• Novartis Investigative Site — South Miami, Florida, United States
• Novartis Investigative Site — Arlington Heights, Illinois, United States
• Novartis Investigative Site — Champaign, Illinois, United States
• Novartis Investigative Site — Skokie, Illinois, United States
• Novartis Investigative Site — Indianapolis, Indiana, United States
• Novartis Investigative Site — Overland Park, Kansas, United States
• Novartis Investigative Site — Owensboro, Kentucky, United States
• Novartis Investigative Site — Boston, Massachusetts, United States
• Novartis Investigative Site — St Louis, Missouri, United States
• Novartis Investigative Site — East Windsor, New Jersey, United States
• Novartis Investigative Site — Forest Hills, New York, United States
• Novartis Investigative Site — Portland, Oregon, United States
• Novartis Investigative Site — Portland, Oregon, United States
• Novartis Investigative Site — Greer, South Carolina, United States
• Novartis Investigative Site — Dallas, Texas, United States
• Novartis Investigative Site — Houston, Texas, United States
• Novartis Investigative Site — San Antonio, Texas, United States
• Novartis Investigative Site — Norfolk, Virginia, United States
• Novartis Investigative Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.